Resources previously available on this page can be accessed via the archives. Given the changing nature of the pandemic, beginning in September 2022, we have archived much of the content from this page in an effort to maintain a more streamlined resource, with a focus on current management of immunosuppressed patients and hematologic complications of the disease. Food and Drug AdministrationĮditor’s Note: Since the onset of the novel coronavirus (SARS-CoV-2) outbreak in early 2020, ASH has maintained this webpage to provide information relevant to its membership, to individuals with hematologic conditions, and to the physicians and advanced practice providers who care for them. FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals (U.S.COVID-19 Vaccines for People who are Moderately or Severely Immunocompromised (Centers for Disease Control and Prevention).Latest Guidance From Health Care Agencies.Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.Latest Covid-19 Resources from ASH Publications.Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Treatment of COVID-19 in Immunocompromised Patients With Hematologic Conditions (Version 1.0 last updated September 13, 2022).Prevention of COVID-19 in Immunocompromised Patients With Hematologic Conditions (Version 1.0 last updated September 13, 2022). COVID-19 and Vaccination for HCT and CAR T Cell Recipients (Version 5.0 last updated March 22, 2022).Vaccine-induced Immune Thrombotic Thrombocytopenia (Version 1.9 last updated May 9, 2022).Jim Quanci's blog on partnering with large companies.(Updated September 13, 2022) Current Frequently Asked Clinical Questions COVID-19 Treatment and Prevention Isaac Rodriguez's AutoCAD Civil 3D developer blog Our DevBlog for Design, Lifecycle and Simulation technologies.Ĭyrille Fauvel's Maya platform developer blog - Autodesk Media and Entertainment technology. Our DevBlog for Infrastructure Modeling technology APIs. Our DevBlog for Cloud and Mobile technologies with a strong emphasis on the Autodesk Forge APIs. Our DevBlog for AutoCAD and other platform technology APIs. Our DevBlog for Revit, Navisworks, AEC and BIM technology APIs. Please enable JavaScript if you would like to comment on this blog. ed.SelectCrossingWindow(p1, p3, selFilter) Įd.WriteMessage( "\nDid not find entities") This example uses a filter to only select lines. If the entities are visible, then this will get the entities in the area defined by the points. Instead of using SelectCrossingWindow use SelectCrossingPolygon(). Change the UCS back to world before you run the code and you will see the entities that are inside or cross the second rectangle are selected. Then go to the non plan view, change the UCS to view and draw another rectangle by snapping to the points used for the first rectangle. To see the selection area for the crossing window, in WCS (plan view) draw a rectangle using the REC command using the points used for the crossing window. The selection area using SelectCrossingWindow() is going to be a rectangular shape in WCS that is horizontal. If the view is not a plan view then some of the entities inside of the window defined by the points are not included in the selection. I am using Editor SelectCrossingWindow to select Entities.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |